About maravai lifesciences holdings inc - MRVI
Maravai Lifesciences Holdings, Inc. engages in providing products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. The firm’s brands include TriLink BioTechnologies, Cygnus, Glen Research, and Alphazyme. It operates through the TriLink and Cygnus segments. The TriLink segment manufactures and sells products used in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The Cygnus segment sells biologic safety testing products and highly specialized analytical products for use in biologic manufacturing process development, including custom product-specific antibody and assay development services. It also operates through the following geographical segments: North America, Asia Pacific, Europe, the Middle East, and Africa, and Latin and Central America. The company was founded by Eric Tardif and Carl W. Hull in March 2014 and is headquartered in San Diego, CA.
MRVI At a Glance
Maravai Lifesciences Holdings, Inc.
10770 Wateridge Circle
San Diego, California 92121
| Phone | 1-858-546-0004 | Revenue | 185.74M | |
| Industry | Biotechnology | Net Income | -130,773,000.00 | |
| Sector | Health Technology | Employees | 435 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
MRVI Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 2.526 |
| Price to Book Ratio | 2.224 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -21.888 |
| Enterprise Value to Sales | 4.185 |
| Total Debt to Enterprise Value | 0.469 |
MRVI Efficiency
| Revenue/Employee | 426,995.402 |
| Income Per Employee | -300,627.586 |
| Receivables Turnover | 7.285 |
| Total Asset Turnover | 0.209 |
MRVI Liquidity
| Current Ratio | 6.596 |
| Quick Ratio | 5.694 |
| Cash Ratio | 4.829 |
MRVI Profitability
| Gross Margin | 16.954 |
| Operating Margin | -51.677 |
| Pretax Margin | -126.505 |
| Net Margin | -70.405 |
| Return on Assets | -14.703 |
| Return on Equity | -48.644 |
| Return on Total Capital | -22.661 |
| Return on Invested Capital | -20.904 |
MRVI Capital Structure
| Total Debt to Total Equity | 171.725 |
| Total Debt to Total Capital | 63.198 |
| Total Debt to Total Assets | 47.329 |
| Long-Term Debt to Equity | 165.038 |
| Long-Term Debt to Total Capital | 60.737 |